Condition: Pemphigus · Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with pemphigus.
This description comes directly from the study's public registry record.
Hang Li · 0086-010-66119025 · bdyyec@163.com
Always discuss trial participation with your own doctor first.
| Peking University First Hospital | Beijing, China | Recruiting |
| The Second Xiangya Hospital of Central South University | Changsha, China | Recruiting |
| Chengdu Second People's Hospital | Chengdu, China | Recruiting |
| West China Hospital, Sichuan University | Chengdu, China | Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, China | Recruiting |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou, China | Recruiting |
| Dermatology Hospital of Southern Medical University | Guangzhou, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, China | Recruiting |
| Shandong First Medical University-Affiliated Skin Hospital | Jinan, China | Recruiting |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, China | Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06454357